SciELO - Scientific Electronic Library Online

 
vol.35 número10Nível socioeconômico ao longo da vida e índice de massa corporal: uma revisão sistemática e metanáliseAnálise da qualidade da informação autorreferida sobre duração do sono de escolares do Estudo de Riscos Cardiovasculares em Adolescentes (ERICA) índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Cadernos de Saúde Pública

versão impressa ISSN 0102-311Xversão On-line ISSN 1678-4464

Resumo

FERREIRA NETO, Paula Teixeira Pinto; NUNES, Patrícia Helena Castro  e  VARGAS, Marco Antonio. Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges. Cad. Saúde Pública [online]. 2019, vol.35, n.10, e00053519.  Epub 14-Out-2019. ISSN 1678-4464.  https://doi.org/10.1590/0102-311x00053519.

Biological products have sparked a worldwide therapeutic revolution. However, the high cost of these products threatens health systems’ sustainability. The development of copies is considered an economic alternative, but due to the products’ complexity, many concepts used in generic drugs do not apply. Interchangeability between biologicals poses a regulatory challenge. This essay discusses the main regulatory challenges for establishing criteria for interchangeability between new biologicals and their copies in the scope of the Brazilian Unified National Health System (SUS), considering the guidelines adopted by the world’s main drug regulatory agencies concerning interchangeability and the prevailing Brazilian regulatory framework on this issue. Concerns related to the interchangeability of biologicals include automatic substitution, nomenclature, pharmacovigilance, immunogenicity, and extrapolation of therapeutic indications and clinical data from new biologicals to their copies. While the clinical success and economic benefits of switching from new biologicals to their biosimilars have already been observed, the heterogeneity between countries in the regulatory barriers to the approval of copies of biologicals should be taken into consideration during the regulation of interchangeability of biologicals in Brazil.

Palavras-chave : Interchange of Drugs; Biological Products; Biosimilar Pharmaceuticals; Unified Health System.

        · resumo em Português | Espanhol     · texto em Português     · Português ( pdf )